AbbVie Inc.
HealthcareNYSE:ABBV · New York Stock Exchange
+$2.42 today
Vol 2.08M · Avg 6.53M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$62.8B of revenue converted into $3.6B of net income for the selected period. Gross margin is 70.7% and net margin is 5.7%, showing how much revenue survives after costs and taxes. EPS is $2.04, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $61.2B +8.6% | $56.3B +3.7% | $54.3B -6.4% | $58.1B +3.3% | $56.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $18.2B +7.7% | $16.9B -17.2% | $20.4B +17.2% | $17.4B -0.2% | $17.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $43.0B +8.9% | $39.4B +16.3% | $33.9B -16.6% | $40.6B +4.9% | $38.8B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 70.2% +0.2pp | 70.0% +7.6pp | 62.4% -7.6pp | 70.0% +1.0pp | 69.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $9.1B -28.9% | $12.8B +66.7% | $7.7B +17.9% | $6.5B -19.1% | $8.0B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $14.0B -5.0% | $14.8B +14.6% | $12.9B -15.6% | $15.3B +23.6% | $12.3B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $22.9B -24.5% | $30.3B +43.3% | $21.1B -6.1% | $22.5B +8.1% | $20.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $8.1B -2.9% | $8.4B -3.6% | $8.7B +2.7% | $8.5B -0.6% | $8.5B | $374.2M | $1.2B | $631.8M |
| EBITDA | $17.6B +18.2% | $14.9B -13.2% | $17.2B -29.0% | $24.2B +1.0% | $23.9B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 28.8% +2.4pp | 26.5% -5.1pp | 31.6% -10.0pp | 41.6% -0.9pp | 42.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $20.1B +119.9% | $9.1B -28.4% | $12.8B -29.6% | $18.1B +1.1% | $17.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 32.8% +16.6pp | 16.2% -7.3pp | 23.5% -7.7pp | 31.2% -0.7pp | 31.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $266.0M -59.0% | $648.0M +20.0% | $540.0M +190.3% | $186.0M +376.9% | $39.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.9B +3.0% | $2.8B +26.3% | $2.2B -0.3% | $2.2B -8.0% | $2.4B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$13.5B -148.9% | -$5.4B +16.7% | -$6.5B -40.2% | -$4.6B +6.0% | -$4.9B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $6.6B +77.5% | $3.7B -40.5% | $6.3B -53.6% | $13.5B +3.8% | $13.0B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 10.8% +4.2pp | 6.6% -4.9pp | 11.5% -11.7pp | 23.2% +0.1pp | 23.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.4B +514.7% | -$570.0M -141.4% | $1.4B -15.6% | $1.6B +13.3% | $1.4B | $1.3B | -$1.6B | $745.2M |
| Net Income | $4.2B -1.2% | $4.3B -12.0% | $4.9B -58.9% | $11.8B +2.5% | $11.5B | $4.9B | $4.8B | $4.7B |
| Net Margin | 6.9% -0.7pp | 7.6% -1.4pp | 9.0% -11.4pp | 20.4% -0.2pp | 20.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -1.2% | $2 -12.1% | $3 -58.9% | $7 +2.6% | $6 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -0.8% | $2 -12.1% | $3 -59.0% | $7 +2.8% | $6 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.8B +0.6% | $1.8B +0.1% | $1.8B -0.2% | $1.8B +0.1% | $1.8B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.8B +0.1% | $1.8B +0.0% | $1.8B -0.3% | $1.8B +0.1% | $1.8B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Johnson & Johnson
NYSE:JNJ
$578.11B
UnitedHealth Group Incorporated
NYSE:UNH
$370.46B
Merck & Co., Inc.
NYSE:MRK
$296.38B
Novartis AG
NYSE:NVS
$292.82B
AstraZeneca PLC
NYSE:AZN
$278.78B
Novo Nordisk A/S
NYSE:NVO
$196.35B
Amgen Inc.
NASDAQ:AMGN
$191.18B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.63B
Pfizer Inc.
NYSE:PFE
$149.30B
Sanofi
NASDAQ:SNY
$106.49B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ABBV generate?
AbbVie Inc. (ABBV) reported $61.16B of revenue in fiscal 2025.
Is ABBV profitable?
AbbVie Inc. (ABBV) reported $4.23B of net income, with a net margin of 6.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.